• CD9 expression enhances the CXCL12-induced migration of pre-B leukemic lymphocytes via RAC1 signaling.
INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, accounting for 25% of all pediatric cancers and 75% of all cases of childhood malignant blood disease. In most cases (85%), ALL affects the B lineage, giving rise to a heterogeneous group of diseases displaying different genetic abnormalities.
Five-year event-free survival rates have improved 1 , but about 20% of children suffer from ALL relapse in the bone marrow (BM) or at extramedullary sites, such as the testes or ovaries, these sites being particularly frequently affected in cases of late relapse [2] [3] [4] . It has been suggested that late relapses originate from a preleukemic clone that persists after treatment 5, 6 . This clone is present at the extramedullary site,
where it may undergo new genetic alterations, generating a "new" leukemic clone.
We have shown that several lymphoblastic leukemias can be distinguished on the basis of their CD9 expression 7, 8 . CD9 is a protein belonging to the tetraspanin superfamily. Tetraspanins are small proteins with a highly conserved tertiary structure consisting of four transmembrane domains 9 . They are involved in many biological pathways, due to their ability to associate with a wide variety of other transmembrane proteins, most of which are tissue-specific 10 . Together, these proteins form a structural platform, referred to as the tetraspanin web, and play an important role in signaling pathways 10, 11 . CD9 has been implicated in various physiological processes, such as motility, adhesion and fertilization 12 . It also plays a critical role in several pathological processes, including tumor progression and solid tumor metastasis 13, 14 . Nevertheless its modes of action remain unclear and are highly dependent on cell type and molecular partner [10] [11] [12] 15, 16 . In hematopoietic cells, CD9 expression depends on the stage of differentiation and the location of the cell 16 .
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or SDF1α (stromal cell-derived factor-1) is a chemokine from the CXC family.
CXCL12 was initially found to affect the growth of pro-B cells 20 , but has since been shown to be a potent chemoattractant of lymphocytes 21 . Its receptor, CXCR4, is highly expressed on B-cell progenitors and acute leukemia cells and plays a major role in their migration 22, 23 . The CXCL12/CXCR4 axis is thus crucial in hematopoiesis, supporting the homing and engraftment of normal hematopoietic and leukemic stem cells (HSC/LSC) in bone marrow [23] [24] [25] . Disruption of the interaction between CXCR4
and CXCL12 with a selective chemical antagonist of CXCR4 (AMD3100 or plerixafor)
promotes the massive and rapid mobilization of HSCs into the peripheral blood of healthy mice and human volunteers 26 .
The purpose of this study was to investigate the effect of CD9 on the CXCL12-induced motility and engraftment of pre-B leukemic lymphocytes. We identified CD9
as a regulator of pre-B lymphoblast adhesion and a new actor in CXCR4-mediated migration and homing, promoting RAC1 activation in response to CXCL12. We confirmed the activation of the CD9-RAC1 signaling pathway in samples from patients. We demonstrated that CD9 enhanced the dissemination of pre-B leukemic cells to the testis, one of the preferential sites for late relapses of ALL. We therefore hypothesized that CD9, through its effects on migration and homing, may be a key player in late relapses of B-ALL.
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MATERIALS AND METHODS

Cell lines and leukemic cells from patients
The REH and NALM6 pre-B acute lymphoblastic leukemic cell lines were cultured in RPMI 1640 (Life Technologies) supplemented with 10% decomplemented fetal calf serum (FCS) and 1% antibiotics.
Bone marrow (BM) leukemia cells were collected at diagnosis, after informed consent had been obtained, in accordance with the declaration of Helsinki. The protocol was approved by the Ethics Committee of Rennes Hospital (Rennes, France).
Mononuclear cells were isolated from BM by successive centrifugations through MLS medium (Eurobio). μm Transwell microporous polycarbonate membranes (Corning-Costar). We added 0.6 mL CXCL12 (Abcam) (100 ng/ml) or testis tissue-conditioned medium (TCM) to the lower chamber. After five hours of incubation at 37°C, the cells that had migrated were subjected to trypan blue exclusion and counted. The migration rate was determined as the percentage of cells from the input that had migrated.
Cell transfection
Adhesion assay
We coated 96-well plates with 0.1
by incubation overnight at 4°C. We then incubated 5x10 5 
CXCR4 internalization
Cells were stimulated by incubation with CXCL12 (200 ng/ml) for 20 minutes at 37°C and washed in glycine-HCl buffer (50 mM glycine; 150 mM HCl). CXCR4 expression was analyzed by flow cytometry.
Confocal microscopy
Cytospin preparations of cells were fixed in 4% paraformaldehyde for 20 minutes.
Preparations were blocked for 1 h with 5% FCS, supplemented with 0.2 % saponin (Sigma-Aldrich) if permeabilization was required. Slides were incubated overnight at 4°C with a mouse anti-CD9 antibody (1:50; ALB6; Beckman Coulter) and a rabbit anti-CXCR4 antibody (1:50; polyclonal; Abcam) or a rabbit anti-CXCR7 antibody (1:500; Polyclonal; Abcam). They were then incubated for 1 h at room temperature with anti-rabbit DyLight594 antibody or anti-mouse DyLight488 secondary antibodies (1:500; Jackson Immunoresearch). Actin filaments were decorated by incubation for 1 h at room temperature with rhodamine-phalloidin (1:100; Interchim).
Immunoprecipitation assay
Cells were stimulated with CXCL12 (100 ng/ml) for 30 seconds and lysed in 100 Immunoprecipitates were analyzed by western blotting.
Western blot analysis
Cells lysates were separated by electrophoresis in 15% polyacrylamide gels under standard conditions. The separated proteins were blotted onto Hybond TM -C Extra nitrocellulose membranes (GE Healthcare). Immunoblotting was performed with a 1:1000 dilution of mouse anti-RAC1 or rabbit anti-CXCR4 antibody.
Competition assays with permeant peptides
Permeant peptides labeled at the N-terminus with tetramethylrhodamine (TAMRA) and bearing the C-terminal sequence of CD9 or a scrambled sequence were purchased from Lifetein (South Plainfield, NJ): YGRKKRRQRRR-CCAIRRNREMV (CD9); YGRKKRRQRRR-NRACIRERVCM (scrambled). (Fig. 1A) . We found that higher levels of CD9 protein resulted in the adhesion of larger numbers of cells to the fibronectin coat (Fig.1B) . We assessed the role of CD9 in the migration of B-ALL cells, using the CXCL12 chemokine as a chemoattractant. REH cells express high levels of CXCR4 and this expression was not modified by transduction with lentiviruses (Fig.1A ).
Xenograft transplantation and survival analysis
RESULTS
CD9 increases the mobility of REH cells in vitro
0
Passive migration was initially excluded through the use of CXCL12-depleted medium (average migration rate: 3%±1.1%). CD9 enhanced chemotactic migration in vitro (Fig.1C ).
We also used scanning electron microscopy to explore whether CD9 expression induced morphological changes. CD9 downregulation resulted in a significantly smaller number of villi, which were also significantly thinner on REH CD9 low cells than on control cells ( Fig.1D and D' ).
Finally, we investigated whether the phenotype and mobility properties induced by CD9 downregulation affected engraftment capacity in vivo. We performed xenotransplantation in NSG mice. We first checked that proliferation was not affected by CD9 expression (Fig. S1A ). We then assessed bone marrow (BM) invasion after transplantation, at death. BM invasion rates of 97% were recorded at the time of death, consistent with death from leukemia ( Fig. S2 ). We carried out an analysis of survival curves and demonstrated that the injection of REH cells in which CD9 was downregulated was associated with significantly longer survival (Fig. 1E ).
CD9 expression influences the CXCL12/CXCR4-mediated migration of B-ALL cells
We investigated the contribution of CD9 and CXCR4 to cell migration in response to CXCL12. The inhibition of CXCR4 signaling with plerixafor abolished cell migration.
The anti-CD9 antibody decreased migration by almost 47% (average migration rate:
23.51%±10.57%), suggesting a possible role of CD9 in this major migration pathway ( Fig. 2A) . We also explored the contribution of a second CXCL12 receptor, CXCR7, the function of which in hematopoietic cell migration remains a matter of debate. We added a specific synthetic inhibitor of CXCR7 (CCX771) to the experimental system described above. No effect on REH migration was detected (Fig. 2B ). We used 1 1 confocal imaging to localize CD9, CXCR4 and CXCR7 on the cell membrane. Cells were stabilized by cytospin centrifugation at low speed, to conserve their morphology and membrane structures. A merged image of the CD9 and CXCR4 signals showed tight colocalization, confirming that the proteins were located close together on the membrane unlike CD9 and CXCR7 (Fig. 2C) . The same results have been obtained with NALM6 cells, another pre-B cell line (Fig. S3) . We investigated the possible effect on CXCR4 trafficking of the presence of CD9 on the cell membrane, by assessing CXCR4 internalization after stimulation with CXCL12 (Fig. 2D ). The levels of CXCR4 expression after stimulation were similar in REH CD9 high , CD9 medium and CD9 low cells, suggesting that CD9 does not affect CXCR4 signaling through enhanced internalization.
CD9 promotes the formation of actin protrusions in response to CXCL12
We used confocal microscopy to explore the distributions of CD9 and actin. Following stimulation with CXCL12, REH CD9 high cells were found to have long cytoplasmic extensions displaying colocalized CD9 and actin signals (Fig. 3A) . These structures were numerous on REH CD9 high cells, but were clearly less abundant on REH CD9 low cells (Fig. 3B ). The extensions of REH CD9 high cells were also significantly longer, increasing the width of the cell by 77%±36% rather than by the 21%±36% observed for REH CD9 low cells (Fig. 3C ). REH CD9 high cell extensions were also essentially unidirectional, with 88% orientated in the same direction (Fig. 3D ). By contrast, the extensions of REH CD9 low cells were more uniformly organized around the cell. In parallel, we measured a significantly larger increase in F-actin content following CXCL12 stimulation in CD9 high than in CD9 low cells (Fig. S4 ). These data suggest that CD9 promotes the formation of cytoplasmic extensions and the rearrangement of actin in response to CXCL12.
CD9 affects RAC1 activation, thereby affecting REH migration and engraftment
RAC1 is a Rho-GTPase protein known to cycle between an inactive state (GDPbound) and an active state (GTP-bound). RAC1 is activated by CXCL12 in pre-B cells. This activation enhances the formation of actin-rich lamellipodia in diverse cellular functions, including migration 29 .
We investigated the effect of CD9 depletion on RAC1 activation. CXCL12 stimulation increased RAC1-GTP protein levels by a factor of more than 2.5±0.2 in REH CD9 high cells (Fig. 4A ). No such response was observed in REH CD9 medium and CD9 low cells,
suggesting that the modulation of CD9 expression affects RAC1 activation.
This result was confirmed in blasts extracted from fresh BM collected from B-ALL patients on diagnosis (Fig. 4B ). Linear regression analysis revealed a strong correlation between CD9 protein levels (MFI for CD9) and RAC1-GTP/ RAC1 total ratio (r 2 =0.87, Spearman's r=0.76 and p=0,0377).
We further assessed the effect of RAC1 activation on the chemotactic migration of REH cells. REH CD9 high cells were incubated with various concentrations of NSC23766 before the migration assay. NSC23766 prevents RAC1 activation and chemotactic migration in vitro, in a dose-dependent manner (Fig. 4C) . Moreover, the chemotactic migration of REH CD9 high cells was more strongly altered by NSC23766 treatment than that of REH CD9 medium and CD9 low cells, resulting in higher rates of migration for these cells with low levels of CD9 (Fig. 4D ). This finding supports the hypothesis that CD9 is involved in RAC1 activation and affects CXCL12-induced migration.
Finally, we explored the impact of RAC1 downregulation on mouse survival. We used two different shRNAs to generate two cell lines displaying a stable depletion of RAC1
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The C-terminal tail of CD9 is involved in RAC1 activation
We investigated the mechanism by which CD9 protein affects RAC1 activation, using a permeant TAMRA-coupled peptide containing either the C-terminal amino-acid sequence of CD9 or a scrambled sequence. Cells were incubated with each of these peptides separately, at a concentration of 1 µM. After two hours of incubation, the peptides were detectable in the cytoplasm of REH cells and were not trapped in the cytoplasmic membrane (Fig. 5A ).
We investigated RAC1 activation in the presence of the two peptides (Fig. 5B) . The CD9 peptide significantly decreased basal levels of RAC1-GTP (p=0.04) and lower levels of RAC1 activation in response to CXCL12 were reported for this peptide than for the scrambled peptide. Cells expressing the scrambled peptide had long cytoplasmic extensions (Fig. 5C ), most of which (41.6%) were oriented in the same direction (Fig. 5D ). By contrast, cells expressing the CD9 peptide had a smaller number of extensions and their extensions were shorter (Fig. 5C ) and more uniformly distributed around the cell (Fig. 5D ). These findings suggest that CD9 enhances RAC1 activation and actin remodeling via its C-terminal sequence, in response to CXCL12 (Fig. 5E ).
CD9 promotes B-cell chemotactic migration in response to testis-conditioned medium, through RAC1 signaling
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On three independent experiments, the migration induced by the conditioned medium was impaired to similar extents by plerixafor, NSC23766 and the antibody targeting CD9 (Fig. 6B) . Complete CD9 depletion also significantly decreased migration (Fig.   6C ). Similar results were obtained for the chemotactic migration induced by CXCL12
( Fig. S6A and B ) and the conditioned medium ( Fig. 6D ) with NALM6 cell line, which expresses both CD9 and CXCR4.
CD9 improves engraftment in the testis in vivo
We previously showed that CD9 enhanced the chemotactic migration induced by the CXCL12 present in the extracellular matrix of the testis in vitro. We carried out xenografting studies to assess, in vivo, the effect of CD9 depletion on REH cell engraftment in the testis. Four weeks after injection, testis tissues were collected, dissociated, labeled with human pre-B markers and analyzed by cytometry (Fig. 7A) .
We also assessed CD9 expression. We showed that most of the REH cells able to migrate to testis were positive for CD9, even for the REH CD9 low cell line (Fig. 7B ).
This suggests that a CD9-positive subclone within a predominantly CD9-negative population would engraft to the testis tissue more efficiently than the other cells.
Similar results have been reported for NALM6 cells displaying stable downregulation of CD9 (CD9 medium cells with an MFI for CD9 <60) (Fig. 7C) . Three weeks after injection, we observed a small but significant difference in BM homing between 
DISCUSSION
CD9 is one of the best characterized tetraspanins, but the functional involvement of CD9 in the mobility of leukemic blasts has never before been reported. We found that CD9 and CXCR4 were colocalized on the REH cell membrane. We therefore investigated the effect of CD9 on CXCR4 internalization following CXCL12 binding.
CD9 has already been shown to attenuate epidermal growth factor receptor signaling 
RAC1 enhances transendothelial migration across the blood-testis barrier 47 .
In summary (Fig. 5E ), we show here, for the first time, that the tetraspanin CD9 can interfere with CXCL12/CXCR4 signaling by enhancing RAC1 activation in a pre-B ALL cell line and, more importantly, in samples from patients. RAC1 activation enhances actin rearrangement and the formation of cytoplasmic extensions, promoting chemotactic migration towards CXCL12 in the testis, a recognized site of late ALL relapses. These data indicate that CD9 increases the ability of pre-B leukemic cells to disseminate, through its effects on migration and homing, suggesting a possible key role in late relapses of B-ALL, which are currently poorly misunderstood. For n is the number of mice used: REH CD9 high n=7; REH CD9 medium n=14; REH CD9 low n=8;*** p<0.001 ****p<0.0001 in log-rank (Mantel-Cox) tests.
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